Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
precisionmedicineonline5 小时
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
precisionmedicineonline10 小时
Ibrance Plus Frontline Standard Therapy Delays Progression by 15 Months in HER2, HR ...
Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.
Zacks.com on MSN12 小时
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
The momentum is likely to continue. Halozyme is also focused on signing new collaboration deals to aid growth. However, blockbuster drugs like Herceptin and Rituxan that use ENHANZE technology have ...